Company Overview - Beam is focused on next-generation gene editing utilizing CRISPR tools, specifically through a technology called base editing, which allows for precise genome targeting and editing without double-stranded breaks [2]. Key Programs - The company has two major franchises, one of which is in hematology, targeting sickle cell disease with its lead program BEAM-101, which is considered a best-in-class option for patients suffering from this condition [3]. - The next-generation versions of the program aim to provide functional cures in more accessible ways, including non-genotoxic conditioning and in vivo delivery directly to the bone marrow [3].